Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Comerica Bank

Comerica Bank cut its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPNGet Rating) by 9.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 41,453 shares of the specialty pharmaceutical company’s stock after selling 4,485 shares during the period. Comerica Bank owned 0.08% of Supernus Pharmaceuticals worth $1,405,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Polaris Capital Management LLC raised its position in Supernus Pharmaceuticals by 8,769.9% during the 2nd quarter. Polaris Capital Management LLC now owns 2,918,196 shares of the specialty pharmaceutical company’s stock worth $45,611,000 after buying an additional 2,885,296 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Supernus Pharmaceuticals by 108.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 550,081 shares of the specialty pharmaceutical company’s stock worth $17,779,000 after buying an additional 285,737 shares during the last quarter. Millennium Management LLC purchased a new position in Supernus Pharmaceuticals during the 2nd quarter worth approximately $7,063,000. Emerald Advisers LLC raised its position in Supernus Pharmaceuticals by 348.5% during the 3rd quarter. Emerald Advisers LLC now owns 313,477 shares of the specialty pharmaceutical company’s stock worth $10,611,000 after buying an additional 243,577 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust raised its position in Supernus Pharmaceuticals by 350.7% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 273,568 shares of the specialty pharmaceutical company’s stock worth $9,260,000 after buying an additional 212,873 shares during the last quarter. 99.82% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 6,800 shares of Supernus Pharmaceuticals stock in a transaction on Friday, November 11th. The shares were sold at an average price of $34.95, for a total value of $237,660.00. Following the sale, the vice president now owns 1,644 shares of the company’s stock, valued at approximately $57,457.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, VP Padmanabh P. Bhatt sold 6,800 shares of Supernus Pharmaceuticals stock in a transaction on Friday, November 11th. The shares were sold at an average price of $34.95, for a total value of $237,660.00. Following the sale, the vice president now owns 1,644 shares of the company’s stock, valued at approximately $57,457.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Padmanabh P. Bhatt sold 4,826 shares of Supernus Pharmaceuticals stock in a transaction on Tuesday, January 17th. The shares were sold at an average price of $39.92, for a total transaction of $192,653.92. Following the completion of the sale, the vice president now directly owns 1,644 shares in the company, valued at approximately $65,628.48. The disclosure for this sale can be found here. In the last quarter, insiders have sold 69,340 shares of company stock valued at $2,629,303. 7.99% of the stock is owned by company insiders.

Supernus Pharmaceuticals Price Performance

NASDAQ:SUPN opened at $40.31 on Monday. The firm has a market cap of $2.18 billion, a price-to-earnings ratio of 62.98 and a beta of 0.94. The company has a 50 day moving average price of $36.76 and a 200-day moving average price of $34.33. Supernus Pharmaceuticals, Inc. has a 1-year low of $24.95 and a 1-year high of $41.19.

Supernus Pharmaceuticals (NASDAQ:SUPNGet Rating) last posted its earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.29). The firm had revenue of $177.35 million for the quarter, compared to analysts’ expectations of $173.22 million. Supernus Pharmaceuticals had a net margin of 5.72% and a return on equity of 4.51%. On average, sell-side analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.63 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Piper Sandler reduced their price target on shares of Supernus Pharmaceuticals from $38.00 to $36.00 in a research report on Tuesday, October 11th. StockNews.com raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, January 13th.

Supernus Pharmaceuticals Company Profile

(Get Rating)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.

Featured Articles

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPNGet Rating).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.